Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sepsis | 55 | 2024 | 334 | 9.970 |
Why?
|
Shock, Septic | 43 | 2024 | 108 | 8.760 |
Why?
|
Acute Kidney Injury | 24 | 2024 | 322 | 4.430 |
Why?
|
Intensive Care Units, Pediatric | 37 | 2024 | 109 | 3.650 |
Why?
|
Child | 137 | 2024 | 7291 | 3.610 |
Why?
|
Child, Preschool | 76 | 2024 | 3794 | 2.400 |
Why?
|
Critical Illness | 16 | 2024 | 322 | 2.400 |
Why?
|
Systemic Inflammatory Response Syndrome | 15 | 2023 | 53 | 2.220 |
Why?
|
Hematopoietic Stem Cell Transplantation | 14 | 2024 | 918 | 2.180 |
Why?
|
Multiple Organ Failure | 14 | 2024 | 55 | 2.150 |
Why?
|
Infant | 64 | 2024 | 3207 | 2.070 |
Why?
|
Anti-Bacterial Agents | 12 | 2024 | 804 | 1.790 |
Why?
|
Hospital Mortality | 19 | 2024 | 435 | 1.670 |
Why?
|
Adolescent | 68 | 2024 | 9441 | 1.530 |
Why?
|
Biomarkers | 29 | 2024 | 1824 | 1.290 |
Why?
|
Hypotension | 2 | 2020 | 72 | 1.250 |
Why?
|
Critical Care | 13 | 2022 | 398 | 1.230 |
Why?
|
Humans | 155 | 2024 | 91299 | 1.200 |
Why?
|
Retrospective Studies | 50 | 2024 | 9427 | 1.200 |
Why?
|
Anti-Infective Agents | 3 | 2023 | 91 | 1.140 |
Why?
|
Kidney Diseases | 4 | 2023 | 325 | 1.070 |
Why?
|
Time-to-Treatment | 3 | 2024 | 126 | 1.030 |
Why?
|
Vancomycin | 4 | 2022 | 74 | 0.990 |
Why?
|
Respiratory Insufficiency | 8 | 2022 | 179 | 0.940 |
Why?
|
Male | 86 | 2024 | 43392 | 0.900 |
Why?
|
Cytokines | 7 | 2022 | 824 | 0.880 |
Why?
|
Severity of Illness Index | 22 | 2024 | 1898 | 0.870 |
Why?
|
Immunocompromised Host | 2 | 2024 | 144 | 0.870 |
Why?
|
Intensive Care Units | 8 | 2023 | 415 | 0.860 |
Why?
|
Heart Arrest | 4 | 2019 | 282 | 0.830 |
Why?
|
Female | 82 | 2024 | 47301 | 0.830 |
Why?
|
Hospitals, Pediatric | 13 | 2022 | 127 | 0.800 |
Why?
|
Bacterial Infections | 3 | 2020 | 185 | 0.800 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2019 | 405 | 0.800 |
Why?
|
Intubation, Intratracheal | 6 | 2023 | 150 | 0.790 |
Why?
|
Prospective Studies | 31 | 2024 | 4375 | 0.760 |
Why?
|
Shock | 3 | 2021 | 44 | 0.750 |
Why?
|
Practice Guidelines as Topic | 4 | 2024 | 1067 | 0.700 |
Why?
|
Infant, Newborn | 21 | 2024 | 2515 | 0.680 |
Why?
|
Risk Factors | 21 | 2024 | 5622 | 0.660 |
Why?
|
Databases as Topic | 1 | 2019 | 94 | 0.620 |
Why?
|
Extracorporeal Membrane Oxygenation | 4 | 2023 | 201 | 0.610 |
Why?
|
Vaccination | 1 | 2020 | 282 | 0.590 |
Why?
|
Research Design | 3 | 2020 | 594 | 0.570 |
Why?
|
Adaptation, Psychological | 1 | 2018 | 168 | 0.560 |
Why?
|
Heart Diseases | 1 | 2019 | 307 | 0.530 |
Why?
|
Pneumatosis Cystoides Intestinalis | 1 | 2016 | 6 | 0.530 |
Why?
|
Practice Patterns, Physicians' | 3 | 2018 | 610 | 0.520 |
Why?
|
Water-Electrolyte Imbalance | 3 | 2023 | 15 | 0.520 |
Why?
|
Leukemia | 1 | 2018 | 320 | 0.510 |
Why?
|
High-Frequency Ventilation | 2 | 2013 | 10 | 0.500 |
Why?
|
Hydrogen Peroxide | 1 | 2016 | 161 | 0.500 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 267 | 0.490 |
Why?
|
Respiratory Tract Infections | 3 | 2023 | 111 | 0.480 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2017 | 410 | 0.480 |
Why?
|
Immunoglobulins, Intravenous | 4 | 2023 | 65 | 0.480 |
Why?
|
Quality of Life | 3 | 2024 | 1704 | 0.470 |
Why?
|
Organ Dysfunction Scores | 4 | 2022 | 30 | 0.470 |
Why?
|
Prognosis | 17 | 2023 | 3828 | 0.460 |
Why?
|
Respiration, Artificial | 9 | 2024 | 376 | 0.460 |
Why?
|
Electronic Health Records | 3 | 2024 | 360 | 0.460 |
Why?
|
Phenotype | 9 | 2024 | 2489 | 0.440 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 1757 | 0.430 |
Why?
|
Communication | 1 | 2016 | 462 | 0.410 |
Why?
|
Immunotherapy | 4 | 2021 | 705 | 0.400 |
Why?
|
Proprotein Convertase 9 | 2 | 2023 | 20 | 0.390 |
Why?
|
Noninvasive Ventilation | 2 | 2022 | 36 | 0.380 |
Why?
|
United States | 22 | 2024 | 7214 | 0.370 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 325 | 0.360 |
Why?
|
Coronavirus Infections | 3 | 2020 | 310 | 0.360 |
Why?
|
Emergencies | 1 | 2011 | 122 | 0.360 |
Why?
|
Logistic Models | 10 | 2021 | 1218 | 0.360 |
Why?
|
Blood Transfusion | 2 | 2022 | 170 | 0.360 |
Why?
|
Nervous System Diseases | 2 | 2023 | 163 | 0.360 |
Why?
|
Glomerular Filtration Rate | 3 | 2022 | 280 | 0.360 |
Why?
|
Brain Diseases | 2 | 2022 | 191 | 0.360 |
Why?
|
Cohort Studies | 12 | 2024 | 2909 | 0.350 |
Why?
|
Length of Stay | 9 | 2021 | 761 | 0.350 |
Why?
|
Trachea | 1 | 2011 | 292 | 0.350 |
Why?
|
Hospitalization | 11 | 2024 | 904 | 0.350 |
Why?
|
Time Factors | 8 | 2024 | 5394 | 0.330 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 3 | 2021 | 204 | 0.330 |
Why?
|
HSP70 Heat-Shock Proteins | 5 | 2017 | 115 | 0.330 |
Why?
|
Risk Assessment | 13 | 2024 | 2346 | 0.330 |
Why?
|
Drug Monitoring | 2 | 2021 | 119 | 0.320 |
Why?
|
Alzheimer Disease | 2 | 2024 | 521 | 0.320 |
Why?
|
Hypothermia, Induced | 2 | 2021 | 83 | 0.310 |
Why?
|
Betacoronavirus | 3 | 2020 | 266 | 0.310 |
Why?
|
Prevalence | 11 | 2022 | 1267 | 0.300 |
Why?
|
Databases, Factual | 8 | 2020 | 883 | 0.300 |
Why?
|
Algorithms | 5 | 2020 | 1938 | 0.300 |
Why?
|
Young Adult | 15 | 2022 | 6526 | 0.300 |
Why?
|
Out-of-Hospital Cardiac Arrest | 2 | 2021 | 94 | 0.300 |
Why?
|
Resuscitation | 3 | 2017 | 111 | 0.290 |
Why?
|
Chlorides | 2 | 2018 | 104 | 0.290 |
Why?
|
Emergency Service, Hospital | 3 | 2017 | 536 | 0.290 |
Why?
|
Global Health | 4 | 2017 | 194 | 0.290 |
Why?
|
Interleukin-8 | 5 | 2022 | 86 | 0.290 |
Why?
|
Neoplasms | 2 | 2021 | 3060 | 0.290 |
Why?
|
Immunotherapy, Adoptive | 2 | 2021 | 247 | 0.280 |
Why?
|
Antibodies, Monoclonal, Humanized | 5 | 2021 | 972 | 0.280 |
Why?
|
Adrenal Cortex Hormones | 3 | 2018 | 278 | 0.270 |
Why?
|
Matrix Metalloproteinase 8 | 5 | 2017 | 5 | 0.270 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 61 | 0.270 |
Why?
|
Creatinine | 4 | 2023 | 295 | 0.270 |
Why?
|
Influenza, Human | 2 | 2023 | 343 | 0.270 |
Why?
|
Microglia | 2 | 2024 | 109 | 0.270 |
Why?
|
Health Resources | 2 | 2018 | 81 | 0.270 |
Why?
|
Pediatrics | 3 | 2016 | 366 | 0.260 |
Why?
|
Glucocorticoids | 4 | 2023 | 365 | 0.260 |
Why?
|
Disease Models, Animal | 6 | 2024 | 2436 | 0.260 |
Why?
|
Age Factors | 6 | 2021 | 1878 | 0.260 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 21 | 0.250 |
Why?
|
Amyloid beta-Peptides | 2 | 2024 | 214 | 0.250 |
Why?
|
Disease Progression | 4 | 2023 | 1499 | 0.240 |
Why?
|
C-Reactive Protein | 3 | 2023 | 198 | 0.240 |
Why?
|
Pandemics | 5 | 2023 | 795 | 0.240 |
Why?
|
Delirium | 2 | 2024 | 73 | 0.240 |
Why?
|
Granzymes | 4 | 2017 | 94 | 0.240 |
Why?
|
Thrombocytopenia | 2 | 2023 | 186 | 0.230 |
Why?
|
Mannose | 1 | 2024 | 9 | 0.230 |
Why?
|
Renal Replacement Therapy | 2 | 2022 | 36 | 0.230 |
Why?
|
Caspases, Initiator | 1 | 2024 | 1 | 0.230 |
Why?
|
Hypothermia | 2 | 2022 | 26 | 0.230 |
Why?
|
Mice, Transgenic | 3 | 2024 | 1592 | 0.230 |
Why?
|
Complement Membrane Attack Complex | 2 | 2020 | 21 | 0.220 |
Why?
|
Anti-Inflammatory Agents | 2 | 2017 | 350 | 0.220 |
Why?
|
Models, Statistical | 3 | 2020 | 577 | 0.220 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2024 | 128 | 0.220 |
Why?
|
Lung Injury | 1 | 2024 | 57 | 0.220 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 12 | 0.210 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2023 | 26 | 0.210 |
Why?
|
Machine Learning | 2 | 2023 | 279 | 0.210 |
Why?
|
Meningitis, Aseptic | 1 | 2023 | 8 | 0.210 |
Why?
|
Combined Modality Therapy | 3 | 2021 | 1716 | 0.210 |
Why?
|
Dysbiosis | 1 | 2024 | 83 | 0.210 |
Why?
|
Antigens, CD19 | 2 | 2021 | 67 | 0.210 |
Why?
|
Guillain-Barre Syndrome | 1 | 2023 | 17 | 0.210 |
Why?
|
Case-Control Studies | 7 | 2023 | 1884 | 0.210 |
Why?
|
Europe | 3 | 2018 | 330 | 0.210 |
Why?
|
Lipids | 2 | 2024 | 276 | 0.210 |
Why?
|
Chemokine CCL3 | 3 | 2017 | 12 | 0.210 |
Why?
|
Tachycardia, Supraventricular | 1 | 2022 | 16 | 0.210 |
Why?
|
Nanoparticles | 1 | 2024 | 164 | 0.200 |
Why?
|
Immunologic Factors | 2 | 2021 | 172 | 0.200 |
Why?
|
Connective Tissue Diseases | 1 | 2023 | 70 | 0.200 |
Why?
|
Vomiting | 2 | 2016 | 198 | 0.200 |
Why?
|
Muscle Proteins | 2 | 2000 | 132 | 0.200 |
Why?
|
Blood Banks | 1 | 2022 | 7 | 0.200 |
Why?
|
Osteonecrosis | 1 | 2022 | 22 | 0.200 |
Why?
|
Interferon Type I | 1 | 2022 | 191 | 0.190 |
Why?
|
Child, Hospitalized | 1 | 2022 | 36 | 0.190 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 388 | 0.190 |
Why?
|
Blood Specimen Collection | 1 | 2021 | 28 | 0.190 |
Why?
|
Precision Medicine | 2 | 2016 | 424 | 0.180 |
Why?
|
Odds Ratio | 5 | 2022 | 682 | 0.180 |
Why?
|
Transfusion Reaction | 1 | 2021 | 17 | 0.180 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 77 | 0.180 |
Why?
|
Erythrocytes | 1 | 2022 | 255 | 0.180 |
Why?
|
Thrombotic Microangiopathies | 1 | 2020 | 21 | 0.180 |
Why?
|
Inflammation Mediators | 2 | 2020 | 157 | 0.180 |
Why?
|
Mitochondria | 2 | 2014 | 564 | 0.180 |
Why?
|
Vasoconstrictor Agents | 2 | 2020 | 57 | 0.180 |
Why?
|
France | 1 | 2020 | 49 | 0.170 |
Why?
|
Meningitis, Bacterial | 1 | 2020 | 13 | 0.170 |
Why?
|
Intubation | 1 | 2020 | 23 | 0.170 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2000 | 4 | 0.170 |
Why?
|
Fingers | 1 | 2020 | 69 | 0.170 |
Why?
|
Oximetry | 1 | 2020 | 83 | 0.170 |
Why?
|
Nerve Tissue Proteins | 2 | 2000 | 511 | 0.170 |
Why?
|
Hypoxia | 2 | 2023 | 668 | 0.170 |
Why?
|
Epidemiological Monitoring | 1 | 2020 | 38 | 0.170 |
Why?
|
Antimicrobial Stewardship | 1 | 2020 | 23 | 0.170 |
Why?
|
Hyperlactatemia | 1 | 2019 | 1 | 0.170 |
Why?
|
Thiamine | 1 | 2019 | 9 | 0.170 |
Why?
|
ROC Curve | 5 | 2024 | 786 | 0.160 |
Why?
|
Salvage Therapy | 1 | 2021 | 233 | 0.160 |
Why?
|
Hemorrhage | 1 | 2021 | 290 | 0.160 |
Why?
|
Genetic Vectors | 5 | 2014 | 448 | 0.160 |
Why?
|
Genetic Therapy | 3 | 2014 | 376 | 0.160 |
Why?
|
Patient Discharge | 4 | 2023 | 328 | 0.160 |
Why?
|
Anthracyclines | 1 | 2019 | 35 | 0.160 |
Why?
|
Patient Readmission | 1 | 2023 | 367 | 0.160 |
Why?
|
Diagnosis, Differential | 3 | 2021 | 1611 | 0.160 |
Why?
|
Staphylococcal Infections | 1 | 2022 | 274 | 0.160 |
Why?
|
Homeodomain Proteins | 2 | 2000 | 558 | 0.160 |
Why?
|
MicroRNAs | 1 | 2024 | 570 | 0.160 |
Why?
|
Treatment Outcome | 11 | 2021 | 8465 | 0.160 |
Why?
|
Clinical Coding | 1 | 2019 | 24 | 0.160 |
Why?
|
Down Syndrome | 2 | 2016 | 55 | 0.160 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2013 | 320 | 0.150 |
Why?
|
Cell Adhesion Molecules | 1 | 2019 | 166 | 0.150 |
Why?
|
Syndrome | 2 | 2017 | 452 | 0.150 |
Why?
|
Orexins | 1 | 2018 | 8 | 0.150 |
Why?
|
Afibrinogenemia | 1 | 2018 | 1 | 0.150 |
Why?
|
Macrophage Activation Syndrome | 1 | 2018 | 2 | 0.150 |
Why?
|
Nutritional Status | 1 | 2018 | 82 | 0.150 |
Why?
|
Emergency Medical Services | 1 | 2021 | 248 | 0.150 |
Why?
|
Ethical Review | 1 | 2018 | 8 | 0.150 |
Why?
|
Models, Theoretical | 3 | 2015 | 493 | 0.150 |
Why?
|
Malnutrition | 1 | 2018 | 33 | 0.150 |
Why?
|
Kidney | 2 | 2023 | 1155 | 0.150 |
Why?
|
Animals | 17 | 2024 | 27852 | 0.150 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2021 | 332 | 0.150 |
Why?
|
Chest Wall Oscillation | 1 | 2017 | 5 | 0.150 |
Why?
|
Acute Lung Injury | 1 | 2019 | 64 | 0.150 |
Why?
|
Ethics Committees, Research | 1 | 2018 | 34 | 0.150 |
Why?
|
Body Mass Index | 2 | 2018 | 787 | 0.150 |
Why?
|
Hemodynamics | 5 | 2021 | 739 | 0.150 |
Why?
|
Mice | 12 | 2024 | 12029 | 0.150 |
Why?
|
Postoperative Complications | 2 | 2019 | 2352 | 0.140 |
Why?
|
Transcriptome | 3 | 2024 | 687 | 0.140 |
Why?
|
Comorbidity | 2 | 2018 | 966 | 0.140 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2014 | 811 | 0.140 |
Why?
|
User-Computer Interface | 1 | 2019 | 187 | 0.140 |
Why?
|
Drug Prescriptions | 1 | 2019 | 147 | 0.140 |
Why?
|
Aftercare | 3 | 2023 | 88 | 0.140 |
Why?
|
Brain Injuries | 1 | 2020 | 169 | 0.140 |
Why?
|
Metabolic Diseases | 1 | 2018 | 55 | 0.140 |
Why?
|
Clinical Alarms | 1 | 2017 | 16 | 0.140 |
Why?
|
Antibodies, Viral | 4 | 2022 | 313 | 0.140 |
Why?
|
AIDS Vaccines | 2 | 2009 | 10 | 0.140 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2017 | 23 | 0.140 |
Why?
|
Gene Expression Profiling | 3 | 2024 | 1473 | 0.140 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2017 | 57 | 0.140 |
Why?
|
Patient Care Bundles | 1 | 2017 | 21 | 0.140 |
Why?
|
Isotonic Solutions | 1 | 2017 | 17 | 0.140 |
Why?
|
Skin | 1 | 2020 | 588 | 0.140 |
Why?
|
Textbooks as Topic | 1 | 2016 | 2 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 616 | 0.140 |
Why?
|
Immunization, Secondary | 2 | 2009 | 34 | 0.140 |
Why?
|
Sleep Wake Disorders | 1 | 2018 | 119 | 0.140 |
Why?
|
Ultrasonography | 2 | 2021 | 723 | 0.140 |
Why?
|
Interleukin-6 | 1 | 2018 | 269 | 0.140 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2017 | 50 | 0.130 |
Why?
|
Surgical Procedures, Operative | 1 | 2019 | 210 | 0.130 |
Why?
|
Brain | 2 | 2024 | 2334 | 0.130 |
Why?
|
Tumor Lysis Syndrome | 1 | 2016 | 11 | 0.130 |
Why?
|
Incidence | 4 | 2024 | 1601 | 0.130 |
Why?
|
Chest Pain | 1 | 2016 | 42 | 0.130 |
Why?
|
Adult | 11 | 2023 | 27221 | 0.130 |
Why?
|
Orthomyxoviridae | 1 | 2016 | 40 | 0.130 |
Why?
|
Heart | 1 | 2019 | 581 | 0.130 |
Why?
|
Cell- and Tissue-Based Therapy | 1 | 2016 | 58 | 0.130 |
Why?
|
Receptors, Glucocorticoid | 1 | 2017 | 141 | 0.120 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 72 | 0.120 |
Why?
|
Steroids | 1 | 2016 | 173 | 0.120 |
Why?
|
Decision Support Techniques | 1 | 2017 | 171 | 0.120 |
Why?
|
Factor IX | 2 | 2006 | 5 | 0.120 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2017 | 1302 | 0.120 |
Why?
|
Sensitivity and Specificity | 5 | 2020 | 2021 | 0.120 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2015 | 43 | 0.120 |
Why?
|
Virus Diseases | 1 | 2016 | 103 | 0.120 |
Why?
|
Recombinant Fusion Proteins | 1 | 2017 | 566 | 0.120 |
Why?
|
Survival of Motor Neuron 1 Protein | 1 | 2014 | 4 | 0.120 |
Why?
|
Dependovirus | 1 | 2014 | 35 | 0.120 |
Why?
|
Muscular Atrophy, Spinal | 1 | 2014 | 25 | 0.120 |
Why?
|
Models, Biological | 2 | 2019 | 1772 | 0.120 |
Why?
|
Survival Rate | 4 | 2021 | 1901 | 0.120 |
Why?
|
Cross Infection | 1 | 2015 | 152 | 0.110 |
Why?
|
Registries | 1 | 2019 | 828 | 0.110 |
Why?
|
Pulmonary Gas Exchange | 1 | 2013 | 32 | 0.110 |
Why?
|
Point-of-Care Systems | 1 | 2015 | 149 | 0.110 |
Why?
|
Recurrence | 1 | 2017 | 1172 | 0.110 |
Why?
|
Survival Analysis | 4 | 2019 | 1501 | 0.110 |
Why?
|
Stroke | 1 | 2023 | 1009 | 0.110 |
Why?
|
Rats, Sprague-Dawley | 3 | 2022 | 1230 | 0.110 |
Why?
|
Program Evaluation | 1 | 2015 | 313 | 0.110 |
Why?
|
Proteolysis | 1 | 2014 | 118 | 0.110 |
Why?
|
Polymorphism, Genetic | 1 | 2017 | 829 | 0.110 |
Why?
|
Spinal Cord | 1 | 2014 | 256 | 0.110 |
Why?
|
Macrophage Activation | 1 | 2013 | 50 | 0.110 |
Why?
|
Clinical Decision-Making | 1 | 2015 | 283 | 0.110 |
Why?
|
Antibodies, Bispecific | 1 | 2013 | 30 | 0.100 |
Why?
|
Glasgow Coma Scale | 2 | 2024 | 77 | 0.100 |
Why?
|
Immune System Diseases | 1 | 2013 | 27 | 0.100 |
Why?
|
Protein Kinases | 1 | 2014 | 213 | 0.100 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2014 | 175 | 0.100 |
Why?
|
RNA, Messenger | 2 | 2017 | 2034 | 0.100 |
Why?
|
Cell Nucleus | 1 | 2014 | 611 | 0.100 |
Why?
|
Stress, Physiological | 1 | 2014 | 239 | 0.100 |
Why?
|
Gagging | 1 | 2011 | 1 | 0.100 |
Why?
|
Metapneumovirus | 1 | 2011 | 3 | 0.100 |
Why?
|
Paramyxoviridae Infections | 1 | 2011 | 5 | 0.100 |
Why?
|
Respiratory Aspiration | 1 | 2011 | 5 | 0.100 |
Why?
|
Subcutaneous Emphysema | 1 | 2011 | 8 | 0.100 |
Why?
|
Mediastinal Emphysema | 1 | 2011 | 6 | 0.100 |
Why?
|
Clinical Protocols | 3 | 2017 | 158 | 0.100 |
Why?
|
Neuroimaging | 2 | 2024 | 126 | 0.100 |
Why?
|
Philadelphia | 3 | 2017 | 19 | 0.100 |
Why?
|
Positive-Pressure Respiration | 1 | 2011 | 44 | 0.100 |
Why?
|
Predictive Value of Tests | 3 | 2024 | 1750 | 0.090 |
Why?
|
Reproducibility of Results | 4 | 2020 | 2788 | 0.090 |
Why?
|
Immunomodulation | 2 | 2021 | 58 | 0.090 |
Why?
|
Autistic Disorder | 1 | 2011 | 147 | 0.090 |
Why?
|
Cardiopulmonary Resuscitation | 3 | 2018 | 224 | 0.090 |
Why?
|
Equipment Design | 1 | 2011 | 421 | 0.090 |
Why?
|
Chromatography, Liquid | 2 | 2021 | 101 | 0.090 |
Why?
|
Endothelial Cells | 2 | 2023 | 472 | 0.090 |
Why?
|
Bronchoscopy | 1 | 2011 | 166 | 0.080 |
Why?
|
Rats | 3 | 2022 | 4060 | 0.080 |
Why?
|
Adenoviruses, Simian | 1 | 2009 | 2 | 0.080 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 4 | 0.080 |
Why?
|
Acute Disease | 3 | 2018 | 857 | 0.080 |
Why?
|
Radiography | 1 | 2011 | 810 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 3505 | 0.080 |
Why?
|
Neurons | 1 | 2018 | 1599 | 0.080 |
Why?
|
Stroke Volume | 2 | 2023 | 484 | 0.080 |
Why?
|
Gene Expression Regulation | 2 | 2015 | 1998 | 0.080 |
Why?
|
Seizures | 1 | 2011 | 311 | 0.080 |
Why?
|
Pilot Projects | 2 | 2022 | 890 | 0.080 |
Why?
|
Oxygen | 1 | 2013 | 755 | 0.080 |
Why?
|
Adenoviruses, Human | 2 | 2009 | 41 | 0.080 |
Why?
|
Drug Therapy, Combination | 2 | 2021 | 805 | 0.080 |
Why?
|
Morbidity | 2 | 2020 | 151 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 888 | 0.070 |
Why?
|
Decision Trees | 2 | 2019 | 62 | 0.070 |
Why?
|
Neutralization Tests | 2 | 2022 | 80 | 0.070 |
Why?
|
Area Under Curve | 2 | 2019 | 338 | 0.070 |
Why?
|
Fluid Therapy | 2 | 2017 | 53 | 0.070 |
Why?
|
Genome-Wide Association Study | 1 | 2014 | 1718 | 0.070 |
Why?
|
Cell Line, Tumor | 3 | 2018 | 2627 | 0.070 |
Why?
|
Inflammation | 2 | 2024 | 1003 | 0.070 |
Why?
|
Obesity | 2 | 2023 | 994 | 0.060 |
Why?
|
Genotype | 2 | 2023 | 1860 | 0.060 |
Why?
|
Mice, Inbred BALB C | 2 | 2018 | 1102 | 0.060 |
Why?
|
Hepatocytes | 1 | 2006 | 125 | 0.060 |
Why?
|
RNA, Viral | 2 | 2020 | 320 | 0.060 |
Why?
|
Healthcare Disparities | 2 | 2023 | 433 | 0.060 |
Why?
|
Hemophilia B | 1 | 2004 | 5 | 0.060 |
Why?
|
Cause of Death | 2 | 2017 | 270 | 0.060 |
Why?
|
Antagomirs | 1 | 2024 | 4 | 0.060 |
Why?
|
Breast Neoplasms | 1 | 2018 | 3033 | 0.060 |
Why?
|
Adenovirus E1 Proteins | 1 | 2003 | 1 | 0.060 |
Why?
|
HIV Antigens | 1 | 2003 | 4 | 0.060 |
Why?
|
Gene Products, gag | 1 | 2003 | 12 | 0.060 |
Why?
|
Datasets as Topic | 1 | 2024 | 79 | 0.060 |
Why?
|
Endoglin | 1 | 2023 | 21 | 0.050 |
Why?
|
DNA-Binding Proteins | 2 | 2000 | 1248 | 0.050 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2023 | 17 | 0.050 |
Why?
|
Angiopoietin-1 | 1 | 2023 | 7 | 0.050 |
Why?
|
Academic Medical Centers | 2 | 2017 | 390 | 0.050 |
Why?
|
PAX7 Transcription Factor | 2 | 2000 | 4 | 0.050 |
Why?
|
Crowding | 1 | 2023 | 6 | 0.050 |
Why?
|
NF-kappa B p52 Subunit | 1 | 2022 | 5 | 0.050 |
Why?
|
Loss of Function Mutation | 1 | 2023 | 47 | 0.050 |
Why?
|
Administration, Intravenous | 1 | 2023 | 57 | 0.050 |
Why?
|
Renin | 1 | 2023 | 67 | 0.050 |
Why?
|
Family Characteristics | 1 | 2023 | 49 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2020 | 3313 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2016 | 982 | 0.050 |
Why?
|
Masks | 1 | 2023 | 30 | 0.050 |
Why?
|
Lipoproteins | 1 | 2023 | 137 | 0.050 |
Why?
|
Thrombomodulin | 1 | 2022 | 7 | 0.050 |
Why?
|
Immunoassay | 1 | 2022 | 93 | 0.050 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2022 | 75 | 0.050 |
Why?
|
Haploinsufficiency | 1 | 2022 | 67 | 0.050 |
Why?
|
Antigens, Viral | 1 | 2022 | 146 | 0.050 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2022 | 45 | 0.050 |
Why?
|
Blood Component Transfusion | 1 | 2021 | 13 | 0.050 |
Why?
|
Seasons | 1 | 2023 | 242 | 0.050 |
Why?
|
Viral Envelope Proteins | 1 | 2022 | 94 | 0.050 |
Why?
|
Cannula | 1 | 2022 | 54 | 0.050 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2022 | 45 | 0.050 |
Why?
|
Surveys and Questionnaires | 2 | 2022 | 2699 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 207 | 0.050 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2022 | 63 | 0.050 |
Why?
|
Transcription Factors | 2 | 2000 | 1672 | 0.050 |
Why?
|
Italy | 1 | 2021 | 108 | 0.050 |
Why?
|
Autoantibodies | 1 | 2022 | 275 | 0.050 |
Why?
|
Transfusion-Related Acute Lung Injury | 1 | 2021 | 1 | 0.050 |
Why?
|
Minority Groups | 1 | 2022 | 148 | 0.050 |
Why?
|
Public Health Surveillance | 1 | 2021 | 22 | 0.050 |
Why?
|
Canada | 1 | 2021 | 202 | 0.050 |
Why?
|
Arrhythmias, Cardiac | 1 | 2022 | 201 | 0.050 |
Why?
|
Patient Acuity | 1 | 2021 | 35 | 0.050 |
Why?
|
Antifibrinolytic Agents | 1 | 2021 | 43 | 0.050 |
Why?
|
Age Distribution | 1 | 2021 | 198 | 0.040 |
Why?
|
Lymphocyte Activation | 1 | 2003 | 760 | 0.040 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2022 | 122 | 0.040 |
Why?
|
Transplant Recipients | 1 | 2022 | 147 | 0.040 |
Why?
|
Tandem Mass Spectrometry | 1 | 2021 | 105 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2020 | 71 | 0.040 |
Why?
|
Propensity Score | 1 | 2021 | 156 | 0.040 |
Why?
|
Piperacillin | 1 | 2020 | 8 | 0.040 |
Why?
|
Temperature | 1 | 2022 | 404 | 0.040 |
Why?
|
Penicillanic Acid | 1 | 2020 | 12 | 0.040 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 27 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2021 | 3724 | 0.040 |
Why?
|
Erythrocyte Count | 1 | 2020 | 22 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 597 | 0.040 |
Why?
|
HIV Infections | 1 | 2009 | 866 | 0.040 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2020 | 41 | 0.040 |
Why?
|
Streptococcus agalactiae | 1 | 2020 | 11 | 0.040 |
Why?
|
APACHE | 1 | 2020 | 22 | 0.040 |
Why?
|
Forkhead Box Protein O1 | 1 | 2000 | 24 | 0.040 |
Why?
|
Immunoglobulin A | 1 | 2020 | 88 | 0.040 |
Why?
|
Immunoglobulin M | 1 | 2020 | 164 | 0.040 |
Why?
|
Cerebrospinal Fluid | 1 | 2020 | 31 | 0.040 |
Why?
|
Age of Onset | 1 | 2021 | 323 | 0.040 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2000 | 51 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2022 | 434 | 0.040 |
Why?
|
Punctures | 1 | 2019 | 30 | 0.040 |
Why?
|
Ligation | 1 | 2019 | 54 | 0.040 |
Why?
|
Streptococcal Infections | 1 | 2020 | 55 | 0.040 |
Why?
|
False Positive Reactions | 1 | 2020 | 222 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2020 | 224 | 0.040 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2000 | 100 | 0.040 |
Why?
|
Cluster Analysis | 1 | 2020 | 373 | 0.040 |
Why?
|
Fungi | 1 | 2020 | 67 | 0.040 |
Why?
|
Rhabdomyosarcoma | 1 | 1999 | 43 | 0.040 |
Why?
|
Inpatients | 1 | 2023 | 320 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2003 | 609 | 0.040 |
Why?
|
Antibodies, Neutralizing | 1 | 2020 | 125 | 0.040 |
Why?
|
Nephritis, Interstitial | 1 | 2020 | 44 | 0.040 |
Why?
|
Cecum | 1 | 2019 | 74 | 0.040 |
Why?
|
Sarcoma, Ewing | 1 | 1999 | 42 | 0.040 |
Why?
|
Regression Analysis | 1 | 2021 | 592 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 375 | 0.040 |
Why?
|
Guidelines as Topic | 1 | 2020 | 163 | 0.040 |
Why?
|
Lipocalin-2 | 1 | 2019 | 37 | 0.040 |
Why?
|
Viruses | 1 | 2020 | 78 | 0.040 |
Why?
|
Cystatin C | 1 | 2019 | 27 | 0.040 |
Why?
|
Electroencephalography | 1 | 2024 | 767 | 0.040 |
Why?
|
NF-kappa B | 1 | 2022 | 469 | 0.040 |
Why?
|
Osteopontin | 1 | 2019 | 47 | 0.040 |
Why?
|
Lactic Acid | 1 | 2019 | 96 | 0.040 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2020 | 74 | 0.040 |
Why?
|
Decision Support Systems, Clinical | 1 | 2020 | 104 | 0.040 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 618 | 0.040 |
Why?
|
DNA Methylation | 1 | 2024 | 673 | 0.040 |
Why?
|
Translocation, Genetic | 1 | 2000 | 264 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2022 | 443 | 0.040 |
Why?
|
South America | 1 | 2018 | 35 | 0.040 |
Why?
|
Forkhead Transcription Factors | 1 | 2000 | 173 | 0.040 |
Why?
|
Linear Models | 1 | 2020 | 426 | 0.040 |
Why?
|
Asia | 1 | 2018 | 102 | 0.040 |
Why?
|
Microbiota | 1 | 2024 | 411 | 0.040 |
Why?
|
Orexin Receptor Antagonists | 1 | 2018 | 1 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2020 | 477 | 0.040 |
Why?
|
Ghrelin | 1 | 2018 | 29 | 0.040 |
Why?
|
Hyperphagia | 1 | 2018 | 36 | 0.040 |
Why?
|
Recovery of Function | 1 | 2020 | 310 | 0.040 |
Why?
|
Coma | 1 | 2018 | 47 | 0.040 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2021 | 213 | 0.040 |
Why?
|
Neurosurgery | 1 | 2020 | 105 | 0.040 |
Why?
|
Hospital Costs | 1 | 2019 | 113 | 0.040 |
Why?
|
North America | 1 | 2018 | 188 | 0.040 |
Why?
|
Neutrophils | 1 | 2019 | 315 | 0.040 |
Why?
|
Leptin | 1 | 2018 | 103 | 0.040 |
Why?
|
Infant, Premature | 1 | 2020 | 299 | 0.040 |
Why?
|
Ohio | 1 | 2017 | 41 | 0.040 |
Why?
|
Calcitonin | 1 | 2017 | 38 | 0.040 |
Why?
|
International Cooperation | 1 | 2017 | 126 | 0.040 |
Why?
|
Serum Amyloid A Protein | 1 | 2017 | 25 | 0.040 |
Why?
|
Lung | 1 | 2024 | 1326 | 0.040 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2018 | 127 | 0.030 |
Why?
|
Acidosis | 1 | 2017 | 55 | 0.030 |
Why?
|
Vital Signs | 1 | 2017 | 37 | 0.030 |
Why?
|
Cardiovascular Agents | 1 | 2017 | 55 | 0.030 |
Why?
|
Kinetics | 1 | 2019 | 1549 | 0.030 |
Why?
|
Sodium Chloride | 1 | 2017 | 88 | 0.030 |
Why?
|
Chemokines, CC | 1 | 2016 | 37 | 0.030 |
Why?
|
Platelet Count | 1 | 2016 | 93 | 0.030 |
Why?
|
Disabled Children | 1 | 2016 | 44 | 0.030 |
Why?
|
Spleen | 1 | 2017 | 433 | 0.030 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2016 | 36 | 0.030 |
Why?
|
Tertiary Healthcare | 1 | 2015 | 5 | 0.030 |
Why?
|
Nasopharynx | 1 | 2016 | 50 | 0.030 |
Why?
|
Genetic Markers | 1 | 2017 | 477 | 0.030 |
Why?
|
Bacteria | 1 | 2020 | 497 | 0.030 |
Why?
|
Neuroblastoma | 1 | 1999 | 390 | 0.030 |
Why?
|
Myeloblastin | 1 | 2015 | 5 | 0.030 |
Why?
|
Monitoring, Physiologic | 1 | 2017 | 265 | 0.030 |
Why?
|
Specimen Handling | 1 | 2016 | 103 | 0.030 |
Why?
|
Glucose | 1 | 2018 | 631 | 0.030 |
Why?
|
Melanoma | 1 | 1999 | 477 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2015 | 116 | 0.030 |
Why?
|
Anesthesia | 1 | 2017 | 167 | 0.030 |
Why?
|
Patient Outcome Assessment | 1 | 2015 | 85 | 0.030 |
Why?
|
Mathematical Computing | 1 | 2015 | 21 | 0.030 |
Why?
|
Injections, Epidural | 1 | 2014 | 6 | 0.030 |
Why?
|
Motor Activity | 1 | 2017 | 326 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2016 | 288 | 0.030 |
Why?
|
Pan troglodytes | 2 | 2009 | 205 | 0.030 |
Why?
|
Pleural Effusion | 1 | 2015 | 47 | 0.030 |
Why?
|
Macaca fascicularis | 1 | 2014 | 109 | 0.030 |
Why?
|
Fever | 1 | 2015 | 129 | 0.030 |
Why?
|
Serine Endopeptidases | 1 | 2015 | 147 | 0.030 |
Why?
|
Pneumothorax | 1 | 2015 | 53 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2017 | 1008 | 0.030 |
Why?
|
Chaperonin 60 | 1 | 2014 | 7 | 0.030 |
Why?
|
Pregnancy | 1 | 2022 | 3083 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2017 | 383 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 1377 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2014 | 161 | 0.030 |
Why?
|
Transgenes | 1 | 2014 | 185 | 0.030 |
Why?
|
Cardiomyopathies | 1 | 2017 | 271 | 0.030 |
Why?
|
Risk | 1 | 2015 | 658 | 0.030 |
Why?
|
DNA, Complementary | 1 | 2014 | 391 | 0.030 |
Why?
|
Health Status Disparities | 1 | 2016 | 193 | 0.030 |
Why?
|
Sleep | 1 | 2018 | 459 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2014 | 420 | 0.030 |
Why?
|
Caspase 3 | 1 | 2014 | 163 | 0.030 |
Why?
|
Brain Stem | 1 | 2014 | 168 | 0.030 |
Why?
|
Observer Variation | 1 | 2015 | 615 | 0.030 |
Why?
|
Respiratory Rate | 1 | 2013 | 22 | 0.030 |
Why?
|
Consensus | 1 | 2015 | 376 | 0.030 |
Why?
|
Heat-Shock Response | 1 | 2014 | 51 | 0.030 |
Why?
|
Receptors, Interleukin-6 | 1 | 2013 | 18 | 0.030 |
Why?
|
Sex Factors | 1 | 2017 | 1085 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 251 | 0.030 |
Why?
|
Motor Neurons | 1 | 2014 | 178 | 0.030 |
Why?
|
Animals, Newborn | 1 | 2014 | 523 | 0.030 |
Why?
|
Quality Improvement | 1 | 2017 | 460 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 867 | 0.030 |
Why?
|
Mortality | 1 | 2014 | 148 | 0.030 |
Why?
|
Oxygen Consumption | 1 | 2013 | 244 | 0.030 |
Why?
|
Sirolimus | 1 | 2014 | 172 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2014 | 696 | 0.030 |
Why?
|
Mutation | 1 | 2004 | 4210 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2015 | 793 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 854 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2020 | 2445 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2014 | 311 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2014 | 662 | 0.020 |
Why?
|
Burns | 1 | 2013 | 144 | 0.020 |
Why?
|
Cell Survival | 1 | 2014 | 985 | 0.020 |
Why?
|
Biomedical Research | 1 | 2015 | 401 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2015 | 373 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 1936 | 0.020 |
Why?
|
Cerebral Cortex | 1 | 2014 | 592 | 0.020 |
Why?
|
Gene Expression | 1 | 2014 | 1314 | 0.020 |
Why?
|
Simian Immunodeficiency Virus | 1 | 2009 | 17 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2014 | 2060 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2009 | 68 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2009 | 179 | 0.020 |
Why?
|
HIV-1 | 1 | 2009 | 163 | 0.020 |
Why?
|
Apoptosis | 1 | 2014 | 1725 | 0.020 |
Why?
|
Macaca mulatta | 1 | 2009 | 468 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2009 | 454 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2006 | 309 | 0.020 |
Why?
|
Adoptive Transfer | 1 | 2006 | 170 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2006 | 217 | 0.020 |
Why?
|
Gene Transfer Techniques | 1 | 2006 | 153 | 0.020 |
Why?
|
Adenoviridae | 1 | 2006 | 349 | 0.010 |
Why?
|
Codon, Nonsense | 1 | 2004 | 45 | 0.010 |
Why?
|
Immunization Schedule | 1 | 2003 | 21 | 0.010 |
Why?
|
Vaccines, DNA | 1 | 2003 | 18 | 0.010 |
Why?
|
Injections, Intramuscular | 1 | 2003 | 65 | 0.010 |
Why?
|
Vaccinia virus | 1 | 2003 | 19 | 0.010 |
Why?
|
Signal Transduction | 1 | 2015 | 3452 | 0.010 |
Why?
|
Antibody Formation | 1 | 2004 | 174 | 0.010 |
Why?
|
Immune Tolerance | 1 | 2006 | 350 | 0.010 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2003 | 88 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2006 | 323 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2004 | 285 | 0.010 |
Why?
|
HeLa Cells | 1 | 2003 | 517 | 0.010 |
Why?
|
RNA | 1 | 2004 | 589 | 0.010 |
Why?
|
PAX3 Transcription Factor | 1 | 1999 | 11 | 0.010 |
Why?
|
Paired Box Transcription Factors | 1 | 1999 | 52 | 0.010 |
Why?
|
Liver | 1 | 2004 | 1227 | 0.010 |
Why?
|
Cell Line | 1 | 2003 | 2509 | 0.010 |
Why?
|
Plasmids | 1 | 1999 | 292 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1999 | 420 | 0.010 |
Why?
|
Aged | 1 | 2016 | 19621 | 0.010 |
Why?
|
Alternative Splicing | 1 | 1999 | 215 | 0.010 |
Why?
|
Exons | 1 | 1999 | 455 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1999 | 1049 | 0.010 |
Why?
|
Middle Aged | 1 | 2016 | 26638 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1999 | 2078 | 0.010 |
Why?
|
Base Sequence | 1 | 1999 | 2330 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 1999 | 3033 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 1999 | 1164 | 0.010 |
Why?
|
Models, Genetic | 1 | 1999 | 964 | 0.010 |
Why?
|